Clinical Trial: A Study on the Mechanism by Which the CTLA4-SHP1-JAK/STAT Signalling Axis Mediates HBsAg-Specific B-Cell Functional Exhaustion and Strategies for Reversal via Antiviral Therapy (China)

Posted On: 2026-11-04

China, Nov. 4 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Study on the Mechanism by Which the CTLA4-SHP1-JAK/STAT Signalling Axis Mediates HBsAg-Specific B-Cell Functional Exhaustion and Strategies for Reversal via Antiviral Therapy'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135876

Registration Time: 2026/11/03

Type: Observational study

Primary Sponsor: Beijing Ditan Hospital, Capital Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=350630

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: A Study on the Mechanism by Which the CTLA4-SHP1-JAK/STAT Signalling Axis Mediates HBsAg-Specific B-Cell Functional Exhaustion and Strategies for Reversal via Antiviral Therapy (China)